Antiviral Monoclonal Antibodies Safe and Effective in Acute COVID-19

Clear Winner from Operation Warp Speed Goes Unrecognized by Public Health Officials and was Denied to Patients

By Peter A. McCullough, MD, MPH

I would have never thought five years ago that I would be using advanced monoclonal antibodies to treat acute viremia in a potentially fatal illness to help a patient avoid hospitalization or death. Yet, early research done by Dr. Ralph Baric who conceived SARS-CoV-2 in his 2015 papers also anticipated the development of a countermeasures such monoclonal antibodies directed against SARS-CoV-2.

Operation Warp Speed is an impressive public-private partnership to rapidly develop and test countermeasures against COVID-19. It’s main products were vaccines, oral antivirals, and monoclonal antibodies. COVID-19 vaccines, continue to be a debacle with record injuries, disabilities, and death with no proven reductions in hospitalization or death from proper trials. Sadly, Paxlovid and Mulnupiravir were very slow to develop and were not gamechangers in the pandemic.

The clear winner from OWS was its very first acute ambulatory product, monoclonal antibodies. 

(See link for article)



  • Despite impressive results, monoclonal antibodies were repeatedly pulled off the market not for actual losses in efficacy but for predicted losses in efficacy
  • Corrupt government agencies quickly censored, banned, and pulled any and all valuable life-saving treatments. Monoclonal antibodies were pulled due to mutational changes in COVID, yet they continue to push obsolete and ineffective COVID gene therapy injections linked with more adverse events and death than any other vaccine in the history of VAERS.
  • The Biopharmaceutical Complex is obviously committed to a “vaccine”- only strategy despite “experts” admitting the fact they knew the “vaccines” didn’t work.

For more:

%d bloggers like this: